Chronic progressive @entity15 is refractory to many conventional treatments. We performed a pilot study testing @entity5532 ( @entity10775 ) as a candidate in the treatment of chronic progressive @entity15 . @entity10775 was given daily by 8 h subcutaneous infusions at a dose of 2 grams daily for 7 days, followed by 1 gram daily for 7 days. Eighteen of 19 individuals completed the full dose of 21 grams. One @entity1 was unable to complete the course due to @entity390 . No acute deterioration of neurological status was seen during the administration of @entity10775 . No worsening of vision or hearing was noted except that the one @entity1 who was unable to tolerate the medication had a transient reduction in hearing. All @entity1 had a local redness at the injection site. None of the @entity1 had any sudden worsening during or shortly after the treatment. This pilot study suggests that @entity10775 is relatively well tolerated by @entity15 @entity1 when given in a short course of therapy.

XXXX in chronic progressive multiple sclerosis: a pilot study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity5532 :: ('MESH:D003676', 'Chemical') :: ['desferroxamine'] @entity10775 :: ('CHEBI:4356', 'Chemical') :: ['DFO'] @entity15 :: ('MESH:D009103', 'Disease') :: ['Multiple Sclerosis']
@entity5532 :: (MESH:D003676,Chemical) :: ['Desferrioxamine']
